NVO » Topics » a. Annual Report

This excerpt taken from the NVO 6-K filed Feb 9, 2009.
Annual Report will know that Novo Nordisk is managed using the Triple Bottom Line business principle. We assess our performance from three perspectives: financial, social and environmental. As we see it, a business can only be sustainable in the long term if it meets stakeholders’ expectations in relation to all three aspects.

In this report we provide examples of how we conduct our activities in ways that are socially and environmentally responsible. We think a couple of them deserve particular mention.

In November, we announced a new programme to offer diabetes treatment, including free insulin, to 10,000 children in some of the world’s poorest countries. This is part of a five-year programme called ‘Changing the Future for Children with Diabetes’, which begins in 2009. In addition to making free insulin available to a particularly vulnerable population of people with diabetes, the project will also build long-term solutions for distribution of insulin and sustainable diabetes treatment in the world’s poorest countries.

We are well on our way to achieving the ambitious target for CO2 reduction we set for ourselves in 2006 and, as a result of our efforts, the majority of our future electricity supplies will be generated from wind. Just as the financial crisis is global, so is climate change, and everyone must take responsibility for addressing it. We will leave it to the scientists to debate to what extent climate change is human-induced or caused by natural developments that are not related to human activity. There are, however, many reasons, including financial, for managing a business in a way that minimises environmental impact, and we will retain our focus on this in coming years.

This excerpt taken from the NVO 20-F filed Feb 11, 2008.

a. Annual Report

The following pages from our Annual Report 2007, filed on Form 6-K, dated 11 February 2008, are incorporated by reference.

  Page(s) in the Annual Report  
 
 
Business results [8-19]  
Risk management [8-9 ]
Research and development pipeline [16-19]  
Business environment [20-25]  
Corporate governance [42-43]  
Executive remuneration [44-45]  
Board of Directors [46-47]  
Executive Management [48 ]
Shareholder information [49-50]  
Financial highlights [52 ]
Consolidated income statements for the years ended 31 December    
[2005, 2006 and 2007] [54 ]
Consolidated balance sheets at 31 December 2006 and 2007 [55 ]
Consolidated cash flow and financial resources for the years    
ended 31 December [2005, 2006 and 2007] [56 ]
Consolidated statements of changes in equity for the years ended 31    
December [2006 and 2007] [57 ]
Notes to the consolidated financial statements [58-88]  
List of companies in the Novo Nordisk Group [100-101]  
Summary of financial data 2003-2007 [102-103]  
Management Statement [113 ]

Additional required information
Reference is made to note 19 in our Annual Report for additional information regarding valuation and qualifying accounts.

30


Back to Contents

This excerpt taken from the NVO 20-F filed Feb 9, 2007.

a. Annual Report

The following pages from our Annual Report 2006, filed on Form 6-K, dated 9 February 2007, are incorporated by reference.

 
Page(s) in the Annual Report
 
Business results [6-7]  
Management report and discussion 2006 [8-15]  
Research and development pipeline [18-19, 34-35]  
Financial highlights [52]  
Consolidated income statements for the years ended 31 December [2004, 2005 and 2006] [54]  
Consolidated balance sheets at 31 December 2005 and 2006 [55]  
Consolidated cash flow and financial resources for the years ended 31 December [2004, 2005 and 2006] [56]  
Consolidated statements of changes in equity for the years ended 31 December [2005 and 2006] [57]  
Notes to the consolidated financial statements [58-89]  
Note 38, Reconciliation to US GAAP [88-89]  
List of companies in the Novo Nordisk Group [100-101]  
Summary of financial data 2002-2006 [102-103]  
Management Statement [105]  
Corporate governance [108-109]  
Risk management [110-111]  
Board of Directors [112-113]  
Executive Management [114]  
Shareholder information [115-117]  

Additional required information
Reference is made to note 19 in our Annual Report for additional information regarding valuation and qualifying accounts.

33


Back to Contents

This excerpt taken from the NVO 20-F filed Oct 24, 2006.

a. Annual Report

The following pages from the Annual Report 2005, filed on Form 6-K, dated 6 February 2006, are incorporated by reference.

Page(s) in the Annual Report
 

 
Business results[8-13] 
Research and development pipeline[12-13] 
Management report and discussion 2005[42-51] 
Financial highlights[52] 
Corporate governance[54-55] 
Risk management[56-57] 
Consolidated income statements for the years ended 31 December [2003, 2004 and 2005][58] 
Consolidated balance sheets at 31 December 2004 and 2005[59] 
Consolidated cash flow and financial resources for the years ended 31 December [2003, 2004 and 2005][60] 
Consolidated statements of changes in equity for the years ended 31 December [2003, 2004 and 2005][61] 
Notes to the consolidated financial statements[62-91] 
Note 38, Reconciliation to US GAAP[90-91] 
List of companies in the Novo Nordisk Group[100-101] 
Summary of financial data 2001-2005[102-103] 
Management Statement[105] 
Board of Directors[108-109] 
Executive Management[110] 
Shareholder information[111-112] 

33






This excerpt taken from the NVO 20-F filed Feb 6, 2006.

a. Annual Report

The following pages from the Annual Report 2005, filed on Form 6-K, dated 6 February 2006, are incorporated by reference.

Page(s) in the Annual Report
 

 
Business results[8-13] 
Research and development pipeline[12-13] 
Management report and discussion 2005[42-51] 
Financial highlights[52] 
Corporate governance[54-55] 
Risk management[56-57] 
Consolidated income statements for the years ended 31 December [2003, 2004 and 2005][58] 
Consolidated balance sheets at 31 December 2004 and 2005[59] 
Consolidated cash flow and financial resources for the years ended 31 December [2003, 2004 and 2005][60] 
Consolidated statements of changes in equity for the years ended 31 December [2003, 2004 and 2005][61] 
Notes to the consolidated financial statements[62-91] 
Note 38, Reconciliation to US GAAP[90-91] 
List of companies in the Novo Nordisk Group[100-101] 
Summary of financial data 2001-2005[102-103] 
Management Statement[105] 
Board of Directors[108-109] 
Executive Management[110] 
Shareholder information[111-112] 

33


Back to Contents

This excerpt taken from the NVO 20-F filed Feb 23, 2005.

a. Annual Report

The following pages from the Annual Report 2004, filed on Form 6-K, dated 22 February 2005, are incorporated by reference.

 
Page(s) in the Annual Report
 
Driving Force [10-11]  
Research and development pipeline [26-27]  
Management report and discussion 2004 [41-47]  
Outlook 2005 [46-47]  
Financial highlights [48]  
Corporate governance [54-55]  
Risk management [56-57]  
Consolidated income statements for the years ended 31 December [2002, 2003 and 2004]
[60]
 
Consolidated balance sheets at 31 December 2003 and 2004 [61]  
Consolidated cash flow and financial resources for the years    
ended 31 December [2002, 2003 and 2004] [62]  
Consolidated statements of changes in equity for the years ended 31 December [2002, 2003 and 2004]
[63]
 
Notes to the consolidated financial statements [64-95]  
Note 39, Reconciliation to US GAAP [93-95]  
List of companies in the Novo Nordisk Group [96-97]  
Summary of financial data 2000-2004 [98-99]  
Management Statement [103]  
Board of Directors [106]  
Executive Management [107]  
Shareholder information [108-109]  

32


Back to Contents

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki